FENNEC director granted options for 25,000 shares

FENNEC PHARMACEUTICALS INC. director Khalid Islam received a grant of stock options as part of his equity compensation.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. director Khalid Islam received a grant of stock options as part of his equity compensation. On June 10, 2026, he was awarded a non-qualified stock option to purchase 25,000 Common Shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan. The option is fully vested on the grant date and expires on June 10, 2036. Following this award, Islam holds stock options covering a total of 250,000 shares.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Islam Khalid

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,000	$8.70	$217K

Holdings After Transaction: Stock Option — 250,000 contracts (Direct)

Footnotes (2)

1. F1. On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
2. F2. The option is 100% vested on date of grant.

Key Figures

Option grant size: 25,000 options Exercise price: $8.70 per share Underlying shares: 25,000 Common Shares +3 more

6 metrics

Option grant size 25,000 options Non-qualified stock option granted June 10, 2026

Exercise price $8.70 per share Conversion or exercise price for new options

Underlying shares 25,000 Common Shares Shares purchasable under this option grant

Total options held after grant 250,000 options Total derivative holdings following transaction

Option expiration date June 10, 2036 Final date to exercise the options

Vesting status 100% vested at grant Options fully exercisable on June 10, 2026

Key Terms

non-qualified stock option, Equity Incentive Plan, Common Shares, exercise price

4 terms

non-qualified stock option financial

"Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Equity Incentive Plan financial

"pursuant to the issuer's Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Common Shares financial

"to purchase 25,000 shares of the issuer's common shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price": "8.7000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FENNEC (FENC) director Khalid Islam report in this Form 4?

Khalid Islam reported receiving a grant of stock options to buy 25,000 FENNEC Common Shares at $8.70 per share. These options were issued under the company’s Equity Incentive Plan as part of his compensation.

How many FENNEC (FENC) shares can Khalid Islam purchase with this new option grant?

The new option grant allows Khalid Islam to purchase 25,000 FENNEC Common Shares. Each option corresponds to one share of common stock, giving him potential future ownership if he exercises the options.

What is the exercise price and term of Khalid Islam’s FENNEC (FENC) stock options?

The stock options have an exercise price of $8.70 per Common Share and expire on June 10, 2036. This defines the fixed price he can pay per share and the final date to exercise the options.

When do Khalid Islam’s new FENNEC (FENC) options vest?

The options are 100% vested on the grant date of June 10, 2026. Full vesting at grant means he can exercise any or all of the 25,000 options immediately, subject to plan and trading restrictions.

How many FENNEC (FENC) stock options does Khalid Islam hold after this grant?

After this grant, Khalid Islam holds stock options covering a total of 250,000 shares. This figure reflects all derivative option holdings reported as of the transaction date in this Form 4 filing.

Is Khalid Islam’s FENNEC (FENC) Form 4 transaction an open-market purchase or sale?

The Form 4 reports a grant of stock options, not an open-market trade. The transaction is coded as an acquisition (grant/award) under the company’s Equity Incentive Plan rather than a market buy or sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Islam Khalid

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option(1)	$8.7	06/10/2026		A		25,000		06/10/2026(2)	06/10/2036	Common Shares	25,000	$8.7	250,000	D

Explanation of Responses:

1. On June 10, 2026, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

2. The option is 100% vested on date of grant.

	/s/ Khalid Islam	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)